Fig. 11

Therapeutic targeting of ECM to increase anti-cancer activity. The secreted ECM can be targeted with different strategies, such as interfering with integrin signaling using FAK inhibitors, destabilizing collagen network through inhibition of LOX enzymes using LOXL2 antibodies, degrading hyaluronan using hyaluronidases, and enhancing antifibrotic properties by reducing collagen synthesis and production using collagen inhibitors. CAFs: Cancer-associated fibroblasts; CXCR4: C-X-C chemokine receptor type 4; CTGF: Connective tissue growth factor; FAK: Focal adhesion kinase; FAP: Fibroblast activation protein; FGF: Fibroblast growth factor; LOX: Lysyl oxidases; TGF-β: transforming growth factor-β. This figure has been created with BioRender.com.